Registry-based retrospective cohort study of mortality among adults admitted to intensive care units in İstanbul with hospital acquired pseudomonas aeruginosa bloodstream-infection between 2014–2021
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Tarih
2024Yazar
Derin, OkanŞahin, Meyha
Dumlu, Rıdvan
Başgönül, Sedef
Bayrak, Ahmet Doğukan
Arduç, Şevval
Bayram, Sümeyye
Mikaliyova, Nurlana
Kantürk, Arzu
Öncül, Ahsen
Yıldız Sevgi, Dilek
Gençer, Serap
Bayraktar, Banu
Dökmetaş, İlyas
Mert, Ali
Üst veri
Tüm öğe kaydını gösterKünye
Derin, O., Şahin, M., Dumlu, R., Başgönül, S., Bayrak, A. D., Arduç, Ş. ... Mert, A. (2024). Registry-based retrospective cohort study of mortality among adults admitted to intensive care units in İstanbul with hospital acquired pseudomonas aeruginosa bloodstream-infection between 2014–2021. Antibiotics, 13(1). https://dx.doi.org/10.3390/antibiotics13010090Özet
Background: Managing Pseudomonas aeruginosa bloodstream infections (BSIs) is challenging due to increasing antimicrobial resistance, limited therapeutic options, and high mortality rates. In this study, we aimed to identify 30-day mortality risk factors and assess infectious diseases consultants’ preferences for combination or monotherapy. Methods: The study was conducted in four hospitals in Istanbul, Turkey, involving 140 adult ICU beds and 336,780 ICU-bed-days between 1 January 2014, and 31 December 2021. A total of 157 patients were included in the study. Cox proportional hazard regression was performed to assess the factors on 30-day mortality. Results: The 30-day mortality rate was 44.6% (70/157). Higher Charlson Comorbidity Index (CCI) score, severe sepsis, primary bloodstream infection, being in COVID-19 pandemic period, and infection caused by MDR strain were associated with higher hazard of 30-day mortality. Combination therapy was more commonly used in patients with BSIs with MDR or DTR (difficult-to-treat) strains but did not significantly improve the hazard of 30-day mortality. Conclusions: Targeted interventions and vigilant management strategies are crucial for patients with defined risk factors. While infectious disease consultants tended to favor combination therapy, particularly for drug-resistant strains, our analysis revealed no significant impact on 30-day mortality hazard. The increased incidence of P. aeruginosa BSIs during the pandemic emphasizes the need for infection control measures and appropriate antibiotic prescribing practices.
WoS Q Kategorisi
Q1Scopus Q Kategorisi
Q1Kaynak
AntibioticsCilt
13Sayı
1Koleksiyonlar
- Diğer Yayınlar Koleksiyonu [257]
- Makale Koleksiyonu [3661]
- PubMed İndeksli Yayınlar Koleksiyonu [4066]
- Scopus İndeksli Yayınlar Koleksiyonu [6309]
- WoS İndeksli Yayınlar Koleksiyonu [6448]